4(33) 2012

DOI xxxxxxxx

Varyvonchyk D. V.

EPIDEMIOLOGY OF MALIGNANT MESOTHELIOMA IN UKRAINE (2001-2011)

SI «Institute for Occupational Health of NAMS of Ukraine», Kyiv

Full article (PDF), RUS

Malignant mesothelioma (MM) is a «tumor-indicator» in the assessment of the exposure of the population to asbestos (first of all — to amphibole). 2 645 cases of MM were officially recorded in Ukraine over 2001—2011 (annual number of cases — 240,5 ± 29,0 men-year). Annual morbidity rates of MM for the population of Ukraine are the following (world standard): men — 0,60 ; women — 0,31 per 100 000 of the total population in the year. Such rates are below the world ones (men — 1,11; women — 0,30) and the rates of the WHO European region (men — 1,53; women — 0,37). The median of age for morbidity of MM for the population of Ukraine between men and women is not different (men — 59,5 ± 13,2; women — 62,6 ± 13,1; p > 0,05). The most frequent localization of MM is the pleura (men — 95,3 %, women — 89,8 %). Ukraine at present can be referred to countries with «low» level (> 0,8 per 100 000 of the total population) and with «moderate» rates (19,0—0,1 %-year) increase of the population morbidity of MM in the WHO European region. The increase of the population morbidity of MM in Ukraine is forecasted by the year 2025 up to 0,97 [0,70 — 1,18] per 100 000 population, and in the WHO European region — by 2,68. 3 cases of morbidity of MM of occupational genesis have been recorded in Ukraine over 1992—2011 (2 of them due to exposure to asbestos dust at workplace). It is recorded in Ukraine high rates of: postmortal diagnostics of MM (men — 17,4 %, women — 15,2), antemortem diagnostics of MM at late stages (HI-IV) of the pathological process (men — 72,0 %, women —69,7%). One-year lethality / median of survival of patients with MM in Ukraine makes: men — 78,9 % / 9,5 months; women — 73,8% / 10,7 months; 5-year survival is minimal: men — 2,8 %, women — 5,4 %. The median of survival decreases in the increase of the stage of disease (minimal in the IV stage — 6 months), however even in the detected MM at the earlier stage (I) it is very low (19,3 months), pointing to high rate of malignancy of the given neoplasm.

Key words: malignant mesothelioma (ММ), asbestos, epidemiology, Ukraine, WHO European region

References

  1. Basanetgs A.V., Kharchenko T.D.,Opanasenko M.S. (2002), “Asbestos and the risk of developing occupational cancer”, Zhurnal praktychnoho likarya , 3, 62-65.
  2. Basanets A.V., Opanasenko M.S., Andrusishina I.N. (2002), “ Concentration of trace elements and electrolytes in exudate and blood serum in the differential diagnosis of malignant pleurisy of occupational etiology”, Ukrainskyi pulmonologichnyi zhurnal, 3, 14-18.
  3. Bychkov M. B. Mezotelioma plevry: sovremennaya taktika lecheniya / M. B. Bychkov // Vestnik Moskovskogo onkologicheskogo obshchestva.- 2006.- No 9.- Zasedaniye No 530.
  4. Varyvonchyk D.V. (2012), “Assessment of carcinogenic hazard in asbestos-cement production in Ukraine”, Ukrainian Journal of Occupational Health, 2, 3-13.
  5. Kashanskiy S. V. Mezotelioma v Rossii: sistemnyy obzor 3576 opublikovannykh sluchayev s pozitsiy meditsiny truda / S. V. Kashanskiy // Meditsina truda i promyshlennaya ekologiya.- 2008.- No 3.- S. 15-21.
  6. Kovalevskiy Ye. V. Monitoring professional'nogo kontakta s asbestom kak osnova upravleniya riskom razvitiya professional'nykh zabolevaniy : avtoref. dis. ... d. med. n / Ye. V. Kovalevskiy.- M., 2005.- 322 s.
  7. Kogan F. M. Belaya kniga o belom asbeste (khrizotile) / F. M. Kogan.- Yekaterinburg, 1997.- 71 s..
  8. Likvidatsiya bolezney, vyzyvayemykh asbestom / VOZ.- Dostup na sayte: http://whqlibdoc.who.int/hq/2006/WHO_SDE_OEH_06.03_rus.pdf.
  9. Mezotelioma: rasprostranennost' i modifitsiruyushchiye faktory (literaturnyy obzor) / P. N. Muzalevskiy, YA. N. Shoykhet, A. F. Lazarev, G. Grigoruk // Sibirskiy onkologicheskiy zhurnal.- 2007.- No 2.- S. 77-83.
  10. Yablonskiy P. K. Zlokachestvennaya mezotelioma plevry / P. K. Yablonskiy, A. S. Petrov // Prakticheskaya onkologiya.- 2006.- T 7, No 3.- S. 179-188.
  11. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite) // In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: A Review of Human Carcinogens: Arsenic, Metals, Fibres, and Dusts.- 2012.- Vol. 100C.- Доступ на сайте:http://monographs.iarc.fr/ENG/Mono- graphs/vol100C/mono100C-11.pdf.
  12. Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40 / E. A. Engels, H. A. Katki, N. M. Nielsen [et al.] // J. Natl. Cancer. Inst.- 2003.- No 95.- P. 532-539.
  13. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters / B. Kroczynska, R. Cutrone, M. Bocchetta [et al.] // PNAS.- 2006.- V. 103, No 38.- Р 14128-14133.
  14. Effects of asbestos on initiation of DNA damage, induction of DNA-strand breaks, P53-expression and apoptosis in primary SV40-transformed and malignant human mesothelial cells / B. Burmeister, T. Schwerdtle, Poser, E. Hoffmann [et al.] // Mutat. Res.- 2004.- V. 558.- P 81-92.
  15. Fennell D. A. Genetics and molecular biology of mesothelioma / D. A. Fennell // Recent Results Cancer Res.- 2011.- V. 189.- P. 149-167.
  16. Gazdar A. F. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40 / A.F. Gazdar, M. Carbone // Clin. Lung. Cancer.- 2003.- No 5.- P 177-181.
  17. Hodgson J. T. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure / J. T. Hodgson, A. Darnton // Ann. Occup. Hyg.- 2000.- V. 44.- P 565-601.
  18. Kazan-Allen L. Asbestos and mesothelioma: Worldwide trends / L. Kazan-Allen // Lung. Cancer- 2005.- V. 49, S. 1.- Р 3-8.
  19. Malignant mesothelioma in Australia, 1945-2000 / J. Leigh, P Davidson, L. Hendrie, D. Berry // Am. J. Ind. Med.- 2002.- V. 41.- P. 188-201.
  20. Malignant mesothelioma: attributable risk of asbestos exposure / R. Spirtas, E. F. Heineman, L. Bernstein, G. W. Beebe [et al.] // Occup. Environ. Med.- 1994.- V. 51.- P. 804-811.
  21. Molecular changes in mesothelioma with an impact on prognosis and treatment / D. Jean, J. Daubriac, F. Le Pimpec-Barthes, F. Galateau-Salle [et al.] // Arch. Pathol. Lab. Med.- 2012.- V. 136, No 3.- P. 277-293.
  22. Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German / N. Becker, D. Liebermann, H. Wesch, G. Vankaick // European Journal of Cancer.- 2008.- V. 44, No 9.- Р 1259-1268.
  23. Muscat J. E. Cigarette Smoking, Asbestos Exposure, and Malignant Mesothelioma / J. E. Muscat, L. Wynder // Cancer research.- 1991.- No 51.- Р. 2263-2267.
  24. Pass H. Malignant pleural mesothelioma: Surgical roles and novel therapies / H. Pass // Clinical. Lung. Cancer- 2001.- V. 3, No 2.- P 102-117.
  25. Pershouse M. The role of SV40 in malignant mesothelioma and other human malignancies / M. Pershouse, S. Heivly T Girtsman // Inhal. Toxicol.- 2006.- V. 18, No 12.- R 995-1000.
  26. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends / Montanaro, F. Bray, V. Gennaro, E. Merler [et al.] // Cancer Causes Control.- 2003.- V. 14.- P. 791-803.
  27. Simian virus 40 in human cancer / R.A. Vilchez, C.A. Kozinetz, A.S. Arrington, C.R. Madden [et al.] // Am. J. Med.- 2003.- V. 114.- P. 675-684.
  28. Simian virus 40 transformation, malignant mesothelioma and brain tumors / F. Qi, M. Carbone, H. Yang, G.Gaudino // Expert. Rev. Respir. Med.- 2011.-5, No 5.- P. 683-697.
  29. Simian virus 40-like DNA sequences in human pleural mesothelioma / M. Carbone, H.I. Pass, P. Rizzo, M. Marinetti [et al.] // Oncogene.- 1994.- No 9.- P. 1781-1790.
  30. Surveillance, Epidemiology and End Results, Cancer Statistics Review 1973-1999.- 2003.- Доступ на сайте:http://seercancergov/csr/1973_1999/overview/overview21.pdf.
  31. The European mesothelioma epidemic / J. Peto, A. Decarli, C. La Vecchia, F. Levi [et al.] // Br. J. Cancer- 1999.- V. 79.- P. 666-672.
  32. Tumours of the pleura / In: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart / Ed.: W. D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris / IARC.- Lyon, 2004.- P. 125-144.
  33. Yang H. Mesothelioma epidemiology, carcinogenesis, and pathogenesis / H. Yang, J. R. Testa, M. Carbone // Curr. Treat. Options Oncol.- 2008.- V. 9, No 2-3.- P. 147-157.